Cafoli

Cafoli is an early-stage biotechnology company focused on the development of novel small molecule therapeutics for ophthalmic conditions. The company's primary research efforts are directed toward the design of potent and selective carbonic anhydrase inhibitors intended to treat glaucoma and ocular hypertension. By leveraging specialized medicinal chemistry, Cafoli aims to create treatments with improved ocular bioavailability and reduced systemic side effects compared to current standard-of-care therapies. The company is currently in the pre-clinical phase of development, conducting lead optimization and initial safety studies.